Adverse effects of antiretroviral therapy

Lancet

Volumn 356, Issue 9239, 2000, Pages 1423-1430

  Carr, Andrew ^a   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL FEATURE; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; FATTY LIVER; GRANULOCYTOPENIA; HEADACHE; HEMOLYTIC ANEMIA; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ABUSE; KIDNEY COLIC; LACTIC ACIDEMIA; LIPODYSTROPHY; LIVER TOXICITY; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; PARESTHESIA; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

EID: 0034699898     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02854-3     Document Type: Article

References (66)

1. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
2. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
3. Mitochondrial toxicity of antiviral drugs
4. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
5. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage
6. Fulminant hepatic failure associated with 2'-3'-dideoxyinosine (ddI)
7. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
8. Hepatic failure and lactic acidosis due to fialuridine, an investigational nucleoside analogue for chronic hepatitis B
9. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine
10. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1
11. Rates and risk factors for adverse events associated with didanosine in the expanded access program
12. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management
13. Lactic acidosis in critical illness
14. The treatment of mitochondrial myopathies and encephalomyopathies
15. Pathogenesis and management of HIV-associated drug hypersensitivity
16. Severe adverse cutaneous reactions to drugs
17. Cutaneous disease and drug reactions in HIV infection
18. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
19. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection
20. The effects of a short course of prednisone on the incidence of rash associated with nevirapine
21. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
22. 'Buffalo hump' in men with HIV-1 infection
23. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
24. Diagnosis, prediction, and natural course of HIV protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus
25. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
26. Protease inhibitor-associated hyperglycaemia
27. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients
28. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance
29. Inhibition of adipocyte differentiation by HIV protease inhibitors
30. Stimulation of vitamin A, acid signaling by the HIV protease inhibitor indinavir
31. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
32. Lipodystrophy following antiretroviral therapy of primary HIV infection
33. Clinical progression and virological failure of highly active antiretroviral therapy in HIV-1 patients: A progressive cohort study
34. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
35. Severe premature coronary artery disease with protease inhibitors
36. Myocardial infarction in HIV-infected men receiving protease inhibitors
37. Distribution in lipid metabolism due to HIV infection and its therapy
38. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
39. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities
40. Preliminary guidelines for the evaluation and management of dyslipidaemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the Adult ACTG Cardiovascular Disease Focus Group
41. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone
42. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
43. Liposuction for protease-inhibitor-associated lipodystrophy
44. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
45. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
46. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: An AIDS Clinical Trials Group study
47. Hydroxyurea and HIV: 5 Years later - From antiviral to immune-modulating effects
48. A placebo-controlled trial of didanosine plus stavudine with and without hydroxyurea for HIV infection
49. Changes in renal function associated with indinavir
50. Variations in incidence of indinavir-associated nephrolithiasis among HIV-positive patients
51. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis
52. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir
53. Alopecia associated with indinavir therapy
54. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease
55. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
56. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
57. Acute hepatitis in a patient treated with saquinavir and ritonavir: Absence of cross-toxicity with indinavir
58. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
59. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily regimens in HIV-1-infected individuals
60. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
61. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study
62. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
63. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors
64. Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors
65. Management of possible sexual, injecting-drug-use, or other non occupational exposure to HIV, including consideration related to antiretroviral therapy
66. Zidovudine toxicity in uninfected healthcare workers